family with sequence similarity 107 member AGenealiases: DRR1 · TU3A
Q-omics provides the consensus-scored FAM107A profile across patient tissues and cancer cell-line models. FAM107A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FAM107A is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, FAM107A RNA expression shows 22,907 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where FAM107A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM107A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM107A survival associations across molecular data types. FAM107A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM107A RNA expression–survival associations across cancer types. High FAM107A expression shows unfavorable associations in ACC and BLCA, but favorable associations in KIRC, HNSC, PAAD and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FAM107A RNA expression.
This table summarizes FAM107A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FAM107A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM107A shows lower tumor expression in BLCA, HNSC, KIRC, KICH, KIRP and COAD. The BLCA box plot shows higher FAM107A RNA expression in normal versus tumor tissue (log2 FC = −4.507, t-test p < 0.001).
This table shows molecular features associated with FAM107A in patient tissues and cancer cell lines. In patient samples, FAM107A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM107A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and OVARY.
